Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: Real-world evidence from Greek healthcare workers
dc.creator | Kontopoulou K., Ainatzoglou A., Ifantidou A., Nakas C.T., Gkounti G., Adamopoulos V., Papadopoulos N., Papazisis G. | en |
dc.date.accessioned | 2023-01-31T08:44:05Z | |
dc.date.available | 2023-01-31T08:44:05Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1099/JMM.0.001387 | |
dc.identifier.issn | 00222615 | |
dc.identifier.uri | http://hdl.handle.net/11615/75092 | |
dc.description.abstract | Real-world data regarding the effectiveness, safety and immunogenicity of the Pfizer-BioNTech BNT162b2 mRNA vaccine are accumulating in the literature, suggesting that this vaccine generates high titres of S1-binding IgG antibodies that exhibit potent virus neutralization capacity. This is the first phase IV immunogenicity study to recruit a large number of Greek healthcare workers (n=425) including 63 previously-infected subjects. We measured titres of neutralizing IgGs against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2 14 days post-immunization with the first dose, employing the SARS-CoV-2 IgG II Quant assay. A total of 92.24 % of our study cohort received a positive assay outcome and titres varied with age. Post-hoc analysis revealed that although titres did not significantly differ among participants aged 20-49 years, a significant decline was marked in the age group of 50-59 years, which was further accentuated in subjects aged over 60. Antibody titres escalated significantly among the previously-infected, indicating the potential booster effect of the first dose in that group. © 2021 The Authors. | en |
dc.language.iso | en | en |
dc.source | Journal of Medical Microbiology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114089219&doi=10.1099%2fJMM.0.001387&partnerID=40&md5=65eb48ac6739a2cf3c03e59c35582d26 | |
dc.subject | bnt 162b 2 | en |
dc.subject | comirnaty | en |
dc.subject | immunoglobulin G | en |
dc.subject | messenger RNA | en |
dc.subject | neutralizing antibody | en |
dc.subject | virus spike protein | en |
dc.subject | bnt 162 vaccine | en |
dc.subject | adult | en |
dc.subject | antibody titer | en |
dc.subject | Article | en |
dc.subject | chill | en |
dc.subject | cohort analysis | en |
dc.subject | controlled study | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | drug efficacy | en |
dc.subject | drug safety | en |
dc.subject | evidence based practice | en |
dc.subject | fatigue | en |
dc.subject | female | en |
dc.subject | fever | en |
dc.subject | Greece | en |
dc.subject | headache | en |
dc.subject | health care personnel | en |
dc.subject | human | en |
dc.subject | humoral immunity | en |
dc.subject | immunization | en |
dc.subject | injection site pain | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | myalgia | en |
dc.subject | outcome assessment | en |
dc.subject | receptor binding | en |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
dc.subject | vaccine immunogenicity | en |
dc.subject | young adult | en |
dc.subject | administration and dosage | en |
dc.subject | aged | en |
dc.subject | diagnosis | en |
dc.subject | epidemiology | en |
dc.subject | health care personnel | en |
dc.subject | immunology | en |
dc.subject | prevention and control | en |
dc.subject | receiver operating characteristic | en |
dc.subject | vaccination | en |
dc.subject | virology | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | COVID-19 | en |
dc.subject | COVID-19 Vaccines | en |
dc.subject | Female | en |
dc.subject | Greece | en |
dc.subject | Health Personnel | en |
dc.subject | Humans | en |
dc.subject | Immunogenicity, Vaccine | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Outcome Assessment, Health Care | en |
dc.subject | ROC Curve | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Vaccination | en |
dc.subject | Young Adult | en |
dc.subject | Microbiology Society | en |
dc.title | Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: Real-world evidence from Greek healthcare workers | en |
dc.type | journalArticle | en |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |